Avenacy, a specialty pharmaceutical company committed to supplying critical injectable medications to the U.S. market, entered into an asset-based lending (ABL) agreement with Texas Capital Bank. The agreement provides Avenacy with the financial flexibility to accelerate its growth and support the continued expansion of its product portfolio to better serve healthcare providers, hospitals and patients nationwide.
“The launch of twenty-three products in under two years reflects the strength of our partnership-driven model and commercial execution,” Jeff Yordon, co-founder and CEO of Avenacy, said. “This financing enables us to build on the strong momentum we’ve achieved since inception and continue expanding access to high-quality injectable medications across the U.S. healthcare system.”
The capital from this agreement is designed to enable Avenacy to advance near-term product launches and pursue key initiatives that reinforce its position as a reliable supplier of essential injectable medications. It will also fund strategic investments in the company’s long-term growth portfolio, with a focus on high-return and market-formation products.
FTI Capital Advisors served as financial advisors to Avenacy for this capital raise.
